Global Biologics Drug Market Research Report 2022
Global Biologics Drug Market Overview:
Global Biologics Drug Market Report 2022 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2022-2028.This research study of Biologics Drug involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Biologics Drug Market
The Biologics Drug Market Research report incorporate value chain analysis for each of the product type. Value chain analysis offers in depth information about value addition at each stage.The study includes drivers and restraints for Biologics Drug Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Biologics Drug Market helps user to make precise decision in order to expand their market presence and increase market share.
Impact of COVID-19 on Biologics Drug Market
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Biologics Drug market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Global Biologics Drug Market Segmentation
Global Biologics Drug Market Research report comprises of Porter's five forces analysis to do the detail study about its each segmentation like Product segmentation, End user/application segment analysis and Major key players analysis mentioned as below;
By Type, Biologics Drug market has been segmented into:
Monoclonal Antibodies (mAbs)
Therapeutic Proteins
Vaccines
By Application, Biologics Drug market has been segmented into:
Online Sales
Pharmacy
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Biologics Drug market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Biologics Drug market.
Top Key Players Covered in Biologics Drug market are:
Johnson & Johnson
Merck & Co.
Bristol-Myers Squibb
AbbVie
Amgen
Pfizer
Eli Lilly and Company
F. Hoffmann-La Roche
GlaxoSmithKline
Sanofi
Objective to buy this Report:
1. Biologics Drug analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Biologics Drug market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Global Biologics Drug Market Report 2022 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2022-2028.This research study of Biologics Drug involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Biologics Drug Market
The Biologics Drug Market Research report incorporate value chain analysis for each of the product type. Value chain analysis offers in depth information about value addition at each stage.The study includes drivers and restraints for Biologics Drug Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Biologics Drug Market helps user to make precise decision in order to expand their market presence and increase market share.
Impact of COVID-19 on Biologics Drug Market
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Biologics Drug market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Global Biologics Drug Market Segmentation
Global Biologics Drug Market Research report comprises of Porter's five forces analysis to do the detail study about its each segmentation like Product segmentation, End user/application segment analysis and Major key players analysis mentioned as below;
By Type, Biologics Drug market has been segmented into:
Monoclonal Antibodies (mAbs)
Therapeutic Proteins
Vaccines
By Application, Biologics Drug market has been segmented into:
Online Sales
Pharmacy
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Biologics Drug market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Biologics Drug market.
Top Key Players Covered in Biologics Drug market are:
Johnson & Johnson
Merck & Co.
Bristol-Myers Squibb
AbbVie
Amgen
Pfizer
Eli Lilly and Company
F. Hoffmann-La Roche
GlaxoSmithKline
Sanofi
Objective to buy this Report:
1. Biologics Drug analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Biologics Drug market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
CHAPTER 1: INTRODUCTION
1.1 RESEARCH OBJECTIVES
1.2 RESEARCH METHODOLOGY
1.3 RESEARCH PROCESS
1.4 SCOPE AND COVERAGE
1.4.1 MARKET DEFINITION
1.4.2 KEY QUESTIONS ANSWERED
1.5 MARKET SEGMENTATION
CHAPTER 2:EXECUTIVE SUMMARY
CHAPTER 3:GROWTH OPPORTUNITIES BY SEGMENT
3.1 BY TYPE
3.2 BY APPLICATION
CHAPTER 4: MARKET LANDSCAPE
4.1 PORTER'S FIVE FORCES ANALYSIS
4.1.1 BARGAINING POWER OF SUPPLIER
4.1.2 THREAT OF NEW ENTRANTS
4.1.3 THREAT OF SUBSTITUTES
4.1.4 COMPETITIVE RIVALRY
4.1.5 BARGAINING POWER AMONG BUYERS
4.2 INDUSTRY VALUE CHAIN ANALYSIS
4.3 MARKET DYNAMICS
4.3.1 DRIVERS
4.3.2 RESTRAINTS
4.3.3 OPPORTUNITIES
4.5.4 CHALLENGES
4.4 PESTLE ANALYSIS
4.5 TECHNOLOGICAL ROADMAP
4.6 REGULATORY LANDSCAPE
4.7 SWOT ANALYSIS
4.8 PRICE TREND ANALYSIS
4.9 PATENT ANALYSIS
4.10 ANALYSIS OF THE IMPACT OF COVID-19
4.10.1 IMPACT ON THE OVERALL MARKET
4.10.2 IMPACT ON THE SUPPLY CHAIN
4.10.3 IMPACT ON THE KEY MANUFACTURERS
4.10.4 IMPACT ON THE PRICING
CHAPTER 5: BIOLOGICS DRUG MARKET BY TYPE
5.1 BIOLOGICS DRUG MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
5.2 BIOLOGICS DRUG MARKET OVERVIEW
5.3 MONOCLONAL ANTIBODIES (MABS)
5.3.1 INTRODUCTION AND MARKET OVERVIEW
5.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.3.4 MONOCLONAL ANTIBODIES (MABS): GEOGRAPHIC SEGMENTATION
5.4 THERAPEUTIC PROTEINS
5.4.1 INTRODUCTION AND MARKET OVERVIEW
5.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.4.4 THERAPEUTIC PROTEINS: GEOGRAPHIC SEGMENTATION
5.5 VACCINES
5.5.1 INTRODUCTION AND MARKET OVERVIEW
5.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.5.4 VACCINES: GEOGRAPHIC SEGMENTATION
CHAPTER 6: BIOLOGICS DRUG MARKET BY APPLICATION
6.1 BIOLOGICS DRUG MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
6.2 BIOLOGICS DRUG MARKET OVERVIEW
6.3 ONLINE SALES
6.3.1 INTRODUCTION AND MARKET OVERVIEW
6.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.3.4 ONLINE SALES: GEOGRAPHIC SEGMENTATION
6.4 PHARMACY
6.4.1 INTRODUCTION AND MARKET OVERVIEW
6.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.4.4 PHARMACY: GEOGRAPHIC SEGMENTATION
6.5 OTHERS
6.5.1 INTRODUCTION AND MARKET OVERVIEW
6.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.5.4 OTHERS: GEOGRAPHIC SEGMENTATION
CHAPTER 7: COMPANY PROFILES AND COMPETITIVE ANALYSIS
7.1 COMPETITIVE LANDSCAPE
7.1.1 COMPETITIVE POSITIONING
7.1.2 BIOLOGICS DRUG SALES AND MARKET SHARE BY PLAYERS
7.1.3 INDUSTRY BCG MATRIX
7.1.4 HEAT MAP ANALYSIS
7.1.5 BIOLOGICS DRUG INDUSTRY CONCENTRATION RATIO (CR5 AND HHI)
7.1.6 TOP 5 BIOLOGICS DRUG PLAYERS MARKET SHARE
7.1.7 MERGERS AND ACQUISITIONS
7.1.8 BUSINESS STRATEGIES BY TOP PLAYERS
7.2 JOHNSON & JOHNSON
7.2.1 COMPANY OVERVIEW
7.2.2 KEY EXECUTIVES
7.2.3 COMPANY SNAPSHOT
7.2.4 OPERATING BUSINESS SEGMENTS
7.2.5 PRODUCT PORTFOLIO
7.2.6 BUSINESS PERFORMANCE
7.2.7 KEY STRATEGIC MOVES AND RECENT DEVELOPMENTS
7.2.8 SWOT ANALYSIS
7.3 MERCK & CO.
7.4 BRISTOL-MYERS SQUIBB
7.5 ABBVIE
7.6 AMGEN
7.7 PFIZER
7.8 ELI LILLY AND COMPANY
7.9 F. HOFFMANN-LA ROCHE
7.10 GLAXOSMITHKLINE
7.11 SANOFI
CHAPTER 8: GLOBAL BIOLOGICS DRUG MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
8.1 MARKET OVERVIEW
8.2 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
8.2.1 MONOCLONAL ANTIBODIES (MABS)
8.2.2 THERAPEUTIC PROTEINS
8.2.3 VACCINES
8.3 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
8.3.1 ONLINE SALES
8.3.2 PHARMACY
8.3.3 OTHERS
CHAPTER 9: NORTH AMERICA BIOLOGICS DRUG MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
9.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
9.2 IMPACT OF COVID-19
9.3 KEY PLAYERS
9.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
9.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
9.4.1 MONOCLONAL ANTIBODIES (MABS)
9.4.2 THERAPEUTIC PROTEINS
9.4.3 VACCINES
9.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
9.5.1 ONLINE SALES
9.5.2 PHARMACY
9.5.3 OTHERS
9.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
9.6.1 U.S.
9.6.2 CANADA
9.6.3 MEXICO
CHAPTER 10: EUROPE BIOLOGICS DRUG MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
10.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
10.2 IMPACT OF COVID-19
10.3 KEY PLAYERS
10.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
10.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
10.4.1 MONOCLONAL ANTIBODIES (MABS)
10.4.2 THERAPEUTIC PROTEINS
10.4.3 VACCINES
10.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
10.5.1 ONLINE SALES
10.5.2 PHARMACY
10.5.3 OTHERS
10.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
10.6.1 GERMANY
10.6.2 U.K.
10.6.3 FRANCE
10.6.4 ITALY
10.6.5 RUSSIA
10.6.6 SPAIN
10.6.7 REST OF EUROPE
CHAPTER 11: ASIA-PACIFIC BIOLOGICS DRUG MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
11.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
11.2 IMPACT OF COVID-19
11.3 KEY PLAYERS
11.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
11.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
11.4.1 MONOCLONAL ANTIBODIES (MABS)
11.4.2 THERAPEUTIC PROTEINS
11.4.3 VACCINES
11.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
11.5.1 ONLINE SALES
11.5.2 PHARMACY
11.5.3 OTHERS
11.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
11.6.1 CHINA
11.6.2 INDIA
11.6.3 JAPAN
11.6.4 SINGAPORE
11.6.5 AUSTRALIA
11.6.6 NEW ZEALAND
11.6.7 REST OF APAC
CHAPTER 12: MIDDLE EAST & AFRICA BIOLOGICS DRUG MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
12.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
12.2 IMPACT OF COVID-19
12.3 KEY PLAYERS
12.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
12.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
12.4.1 MONOCLONAL ANTIBODIES (MABS)
12.4.2 THERAPEUTIC PROTEINS
12.4.3 VACCINES
12.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
12.5.1 ONLINE SALES
12.5.2 PHARMACY
12.5.3 OTHERS
12.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
12.6.1 TURKEY
12.6.2 SAUDI ARABIA
12.6.3 IRAN
12.6.4 UAE
12.6.5 AFRICA
12.6.6 REST OF MEA
CHAPTER 13: SOUTH AMERICA BIOLOGICS DRUG MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
13.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
13.2 IMPACT OF COVID-19
13.3 KEY PLAYERS
13.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
13.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
13.4.1 MONOCLONAL ANTIBODIES (MABS)
13.4.2 THERAPEUTIC PROTEINS
13.4.3 VACCINES
13.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
13.5.1 ONLINE SALES
13.5.2 PHARMACY
13.5.3 OTHERS
13.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
13.6.1 BRAZIL
13.6.2 ARGENTINA
13.6.3 REST OF SA
CHAPTER 14 INVESTMENT ANALYSIS
CHAPTER 15 ANALYST VIEWPOINT AND CONCLUSION
1.1 RESEARCH OBJECTIVES
1.2 RESEARCH METHODOLOGY
1.3 RESEARCH PROCESS
1.4 SCOPE AND COVERAGE
1.4.1 MARKET DEFINITION
1.4.2 KEY QUESTIONS ANSWERED
1.5 MARKET SEGMENTATION
CHAPTER 2:EXECUTIVE SUMMARY
CHAPTER 3:GROWTH OPPORTUNITIES BY SEGMENT
3.1 BY TYPE
3.2 BY APPLICATION
CHAPTER 4: MARKET LANDSCAPE
4.1 PORTER'S FIVE FORCES ANALYSIS
4.1.1 BARGAINING POWER OF SUPPLIER
4.1.2 THREAT OF NEW ENTRANTS
4.1.3 THREAT OF SUBSTITUTES
4.1.4 COMPETITIVE RIVALRY
4.1.5 BARGAINING POWER AMONG BUYERS
4.2 INDUSTRY VALUE CHAIN ANALYSIS
4.3 MARKET DYNAMICS
4.3.1 DRIVERS
4.3.2 RESTRAINTS
4.3.3 OPPORTUNITIES
4.5.4 CHALLENGES
4.4 PESTLE ANALYSIS
4.5 TECHNOLOGICAL ROADMAP
4.6 REGULATORY LANDSCAPE
4.7 SWOT ANALYSIS
4.8 PRICE TREND ANALYSIS
4.9 PATENT ANALYSIS
4.10 ANALYSIS OF THE IMPACT OF COVID-19
4.10.1 IMPACT ON THE OVERALL MARKET
4.10.2 IMPACT ON THE SUPPLY CHAIN
4.10.3 IMPACT ON THE KEY MANUFACTURERS
4.10.4 IMPACT ON THE PRICING
CHAPTER 5: BIOLOGICS DRUG MARKET BY TYPE
5.1 BIOLOGICS DRUG MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
5.2 BIOLOGICS DRUG MARKET OVERVIEW
5.3 MONOCLONAL ANTIBODIES (MABS)
5.3.1 INTRODUCTION AND MARKET OVERVIEW
5.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.3.4 MONOCLONAL ANTIBODIES (MABS): GEOGRAPHIC SEGMENTATION
5.4 THERAPEUTIC PROTEINS
5.4.1 INTRODUCTION AND MARKET OVERVIEW
5.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.4.4 THERAPEUTIC PROTEINS: GEOGRAPHIC SEGMENTATION
5.5 VACCINES
5.5.1 INTRODUCTION AND MARKET OVERVIEW
5.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
5.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
5.5.4 VACCINES: GEOGRAPHIC SEGMENTATION
CHAPTER 6: BIOLOGICS DRUG MARKET BY APPLICATION
6.1 BIOLOGICS DRUG MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
6.2 BIOLOGICS DRUG MARKET OVERVIEW
6.3 ONLINE SALES
6.3.1 INTRODUCTION AND MARKET OVERVIEW
6.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.3.4 ONLINE SALES: GEOGRAPHIC SEGMENTATION
6.4 PHARMACY
6.4.1 INTRODUCTION AND MARKET OVERVIEW
6.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.4.4 PHARMACY: GEOGRAPHIC SEGMENTATION
6.5 OTHERS
6.5.1 INTRODUCTION AND MARKET OVERVIEW
6.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
6.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
6.5.4 OTHERS: GEOGRAPHIC SEGMENTATION
CHAPTER 7: COMPANY PROFILES AND COMPETITIVE ANALYSIS
7.1 COMPETITIVE LANDSCAPE
7.1.1 COMPETITIVE POSITIONING
7.1.2 BIOLOGICS DRUG SALES AND MARKET SHARE BY PLAYERS
7.1.3 INDUSTRY BCG MATRIX
7.1.4 HEAT MAP ANALYSIS
7.1.5 BIOLOGICS DRUG INDUSTRY CONCENTRATION RATIO (CR5 AND HHI)
7.1.6 TOP 5 BIOLOGICS DRUG PLAYERS MARKET SHARE
7.1.7 MERGERS AND ACQUISITIONS
7.1.8 BUSINESS STRATEGIES BY TOP PLAYERS
7.2 JOHNSON & JOHNSON
7.2.1 COMPANY OVERVIEW
7.2.2 KEY EXECUTIVES
7.2.3 COMPANY SNAPSHOT
7.2.4 OPERATING BUSINESS SEGMENTS
7.2.5 PRODUCT PORTFOLIO
7.2.6 BUSINESS PERFORMANCE
7.2.7 KEY STRATEGIC MOVES AND RECENT DEVELOPMENTS
7.2.8 SWOT ANALYSIS
7.3 MERCK & CO.
7.4 BRISTOL-MYERS SQUIBB
7.5 ABBVIE
7.6 AMGEN
7.7 PFIZER
7.8 ELI LILLY AND COMPANY
7.9 F. HOFFMANN-LA ROCHE
7.10 GLAXOSMITHKLINE
7.11 SANOFI
CHAPTER 8: GLOBAL BIOLOGICS DRUG MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
8.1 MARKET OVERVIEW
8.2 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
8.2.1 MONOCLONAL ANTIBODIES (MABS)
8.2.2 THERAPEUTIC PROTEINS
8.2.3 VACCINES
8.3 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
8.3.1 ONLINE SALES
8.3.2 PHARMACY
8.3.3 OTHERS
CHAPTER 9: NORTH AMERICA BIOLOGICS DRUG MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
9.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
9.2 IMPACT OF COVID-19
9.3 KEY PLAYERS
9.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
9.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
9.4.1 MONOCLONAL ANTIBODIES (MABS)
9.4.2 THERAPEUTIC PROTEINS
9.4.3 VACCINES
9.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
9.5.1 ONLINE SALES
9.5.2 PHARMACY
9.5.3 OTHERS
9.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
9.6.1 U.S.
9.6.2 CANADA
9.6.3 MEXICO
CHAPTER 10: EUROPE BIOLOGICS DRUG MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
10.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
10.2 IMPACT OF COVID-19
10.3 KEY PLAYERS
10.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
10.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
10.4.1 MONOCLONAL ANTIBODIES (MABS)
10.4.2 THERAPEUTIC PROTEINS
10.4.3 VACCINES
10.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
10.5.1 ONLINE SALES
10.5.2 PHARMACY
10.5.3 OTHERS
10.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
10.6.1 GERMANY
10.6.2 U.K.
10.6.3 FRANCE
10.6.4 ITALY
10.6.5 RUSSIA
10.6.6 SPAIN
10.6.7 REST OF EUROPE
CHAPTER 11: ASIA-PACIFIC BIOLOGICS DRUG MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
11.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
11.2 IMPACT OF COVID-19
11.3 KEY PLAYERS
11.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
11.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
11.4.1 MONOCLONAL ANTIBODIES (MABS)
11.4.2 THERAPEUTIC PROTEINS
11.4.3 VACCINES
11.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
11.5.1 ONLINE SALES
11.5.2 PHARMACY
11.5.3 OTHERS
11.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
11.6.1 CHINA
11.6.2 INDIA
11.6.3 JAPAN
11.6.4 SINGAPORE
11.6.5 AUSTRALIA
11.6.6 NEW ZEALAND
11.6.7 REST OF APAC
CHAPTER 12: MIDDLE EAST & AFRICA BIOLOGICS DRUG MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
12.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
12.2 IMPACT OF COVID-19
12.3 KEY PLAYERS
12.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
12.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
12.4.1 MONOCLONAL ANTIBODIES (MABS)
12.4.2 THERAPEUTIC PROTEINS
12.4.3 VACCINES
12.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
12.5.1 ONLINE SALES
12.5.2 PHARMACY
12.5.3 OTHERS
12.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
12.6.1 TURKEY
12.6.2 SAUDI ARABIA
12.6.3 IRAN
12.6.4 UAE
12.6.5 AFRICA
12.6.6 REST OF MEA
CHAPTER 13: SOUTH AMERICA BIOLOGICS DRUG MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
13.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
13.2 IMPACT OF COVID-19
13.3 KEY PLAYERS
13.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
13.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
13.4.1 MONOCLONAL ANTIBODIES (MABS)
13.4.2 THERAPEUTIC PROTEINS
13.4.3 VACCINES
13.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
13.5.1 ONLINE SALES
13.5.2 PHARMACY
13.5.3 OTHERS
13.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
13.6.1 BRAZIL
13.6.2 ARGENTINA
13.6.3 REST OF SA
CHAPTER 14 INVESTMENT ANALYSIS
CHAPTER 15 ANALYST VIEWPOINT AND CONCLUSION
LIST OF TABLES
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. BIOLOGICS DRUG MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. BIOLOGICS DRUG MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. BIOLOGICS DRUG MARKET COMPETITIVE RIVALRY
TABLE 005. BIOLOGICS DRUG MARKET THREAT OF NEW ENTRANTS
TABLE 006. BIOLOGICS DRUG MARKET THREAT OF SUBSTITUTES
TABLE 007. BIOLOGICS DRUG MARKET BY TYPE
TABLE 008. MONOCLONAL ANTIBODIES (MABS) MARKET OVERVIEW (2016-2028)
TABLE 009. THERAPEUTIC PROTEINS MARKET OVERVIEW (2016-2028)
TABLE 010. VACCINES MARKET OVERVIEW (2016-2028)
TABLE 011. BIOLOGICS DRUG MARKET BY APPLICATION
TABLE 012. ONLINE SALES MARKET OVERVIEW (2016-2028)
TABLE 013. PHARMACY MARKET OVERVIEW (2016-2028)
TABLE 014. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 015. NORTH AMERICA BIOLOGICS DRUG MARKET, BY TYPE (2016-2028)
TABLE 016. NORTH AMERICA BIOLOGICS DRUG MARKET, BY APPLICATION (2016-2028)
TABLE 017. N BIOLOGICS DRUG MARKET, BY COUNTRY (2016-2028)
TABLE 018. EUROPE BIOLOGICS DRUG MARKET, BY TYPE (2016-2028)
TABLE 019. EUROPE BIOLOGICS DRUG MARKET, BY APPLICATION (2016-2028)
TABLE 020. BIOLOGICS DRUG MARKET, BY COUNTRY (2016-2028)
TABLE 021. ASIA PACIFIC BIOLOGICS DRUG MARKET, BY TYPE (2016-2028)
TABLE 022. ASIA PACIFIC BIOLOGICS DRUG MARKET, BY APPLICATION (2016-2028)
TABLE 023. BIOLOGICS DRUG MARKET, BY COUNTRY (2016-2028)
TABLE 024. MIDDLE EAST & AFRICA BIOLOGICS DRUG MARKET, BY TYPE (2016-2028)
TABLE 025. MIDDLE EAST & AFRICA BIOLOGICS DRUG MARKET, BY APPLICATION (2016-2028)
TABLE 026. BIOLOGICS DRUG MARKET, BY COUNTRY (2016-2028)
TABLE 027. SOUTH AMERICA BIOLOGICS DRUG MARKET, BY TYPE (2016-2028)
TABLE 028. SOUTH AMERICA BIOLOGICS DRUG MARKET, BY APPLICATION (2016-2028)
TABLE 029. BIOLOGICS DRUG MARKET, BY COUNTRY (2016-2028)
TABLE 030. JOHNSON & JOHNSON: SNAPSHOT
TABLE 031. JOHNSON & JOHNSON: BUSINESS PERFORMANCE
TABLE 032. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 033. JOHNSON & JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 033. MERCK & CO.: SNAPSHOT
TABLE 034. MERCK & CO.: BUSINESS PERFORMANCE
TABLE 035. MERCK & CO.: PRODUCT PORTFOLIO
TABLE 036. MERCK & CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 036. BRISTOL-MYERS SQUIBB: SNAPSHOT
TABLE 037. BRISTOL-MYERS SQUIBB: BUSINESS PERFORMANCE
TABLE 038. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 039. BRISTOL-MYERS SQUIBB: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 039. ABBVIE: SNAPSHOT
TABLE 040. ABBVIE: BUSINESS PERFORMANCE
TABLE 041. ABBVIE: PRODUCT PORTFOLIO
TABLE 042. ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 042. AMGEN: SNAPSHOT
TABLE 043. AMGEN: BUSINESS PERFORMANCE
TABLE 044. AMGEN: PRODUCT PORTFOLIO
TABLE 045. AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 045. PFIZER: SNAPSHOT
TABLE 046. PFIZER: BUSINESS PERFORMANCE
TABLE 047. PFIZER: PRODUCT PORTFOLIO
TABLE 048. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 048. ELI LILLY AND COMPANY: SNAPSHOT
TABLE 049. ELI LILLY AND COMPANY: BUSINESS PERFORMANCE
TABLE 050. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 051. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 051. F. HOFFMANN-LA ROCHE: SNAPSHOT
TABLE 052. F. HOFFMANN-LA ROCHE: BUSINESS PERFORMANCE
TABLE 053. F. HOFFMANN-LA ROCHE: PRODUCT PORTFOLIO
TABLE 054. F. HOFFMANN-LA ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 054. GLAXOSMITHKLINE: SNAPSHOT
TABLE 055. GLAXOSMITHKLINE: BUSINESS PERFORMANCE
TABLE 056. GLAXOSMITHKLINE: PRODUCT PORTFOLIO
TABLE 057. GLAXOSMITHKLINE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 057. SANOFI: SNAPSHOT
TABLE 058. SANOFI: BUSINESS PERFORMANCE
TABLE 059. SANOFI: PRODUCT PORTFOLIO
TABLE 060. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. BIOLOGICS DRUG MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. BIOLOGICS DRUG MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. BIOLOGICS DRUG MARKET COMPETITIVE RIVALRY
TABLE 005. BIOLOGICS DRUG MARKET THREAT OF NEW ENTRANTS
TABLE 006. BIOLOGICS DRUG MARKET THREAT OF SUBSTITUTES
TABLE 007. BIOLOGICS DRUG MARKET BY TYPE
TABLE 008. MONOCLONAL ANTIBODIES (MABS) MARKET OVERVIEW (2016-2028)
TABLE 009. THERAPEUTIC PROTEINS MARKET OVERVIEW (2016-2028)
TABLE 010. VACCINES MARKET OVERVIEW (2016-2028)
TABLE 011. BIOLOGICS DRUG MARKET BY APPLICATION
TABLE 012. ONLINE SALES MARKET OVERVIEW (2016-2028)
TABLE 013. PHARMACY MARKET OVERVIEW (2016-2028)
TABLE 014. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 015. NORTH AMERICA BIOLOGICS DRUG MARKET, BY TYPE (2016-2028)
TABLE 016. NORTH AMERICA BIOLOGICS DRUG MARKET, BY APPLICATION (2016-2028)
TABLE 017. N BIOLOGICS DRUG MARKET, BY COUNTRY (2016-2028)
TABLE 018. EUROPE BIOLOGICS DRUG MARKET, BY TYPE (2016-2028)
TABLE 019. EUROPE BIOLOGICS DRUG MARKET, BY APPLICATION (2016-2028)
TABLE 020. BIOLOGICS DRUG MARKET, BY COUNTRY (2016-2028)
TABLE 021. ASIA PACIFIC BIOLOGICS DRUG MARKET, BY TYPE (2016-2028)
TABLE 022. ASIA PACIFIC BIOLOGICS DRUG MARKET, BY APPLICATION (2016-2028)
TABLE 023. BIOLOGICS DRUG MARKET, BY COUNTRY (2016-2028)
TABLE 024. MIDDLE EAST & AFRICA BIOLOGICS DRUG MARKET, BY TYPE (2016-2028)
TABLE 025. MIDDLE EAST & AFRICA BIOLOGICS DRUG MARKET, BY APPLICATION (2016-2028)
TABLE 026. BIOLOGICS DRUG MARKET, BY COUNTRY (2016-2028)
TABLE 027. SOUTH AMERICA BIOLOGICS DRUG MARKET, BY TYPE (2016-2028)
TABLE 028. SOUTH AMERICA BIOLOGICS DRUG MARKET, BY APPLICATION (2016-2028)
TABLE 029. BIOLOGICS DRUG MARKET, BY COUNTRY (2016-2028)
TABLE 030. JOHNSON & JOHNSON: SNAPSHOT
TABLE 031. JOHNSON & JOHNSON: BUSINESS PERFORMANCE
TABLE 032. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 033. JOHNSON & JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 033. MERCK & CO.: SNAPSHOT
TABLE 034. MERCK & CO.: BUSINESS PERFORMANCE
TABLE 035. MERCK & CO.: PRODUCT PORTFOLIO
TABLE 036. MERCK & CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 036. BRISTOL-MYERS SQUIBB: SNAPSHOT
TABLE 037. BRISTOL-MYERS SQUIBB: BUSINESS PERFORMANCE
TABLE 038. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 039. BRISTOL-MYERS SQUIBB: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 039. ABBVIE: SNAPSHOT
TABLE 040. ABBVIE: BUSINESS PERFORMANCE
TABLE 041. ABBVIE: PRODUCT PORTFOLIO
TABLE 042. ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 042. AMGEN: SNAPSHOT
TABLE 043. AMGEN: BUSINESS PERFORMANCE
TABLE 044. AMGEN: PRODUCT PORTFOLIO
TABLE 045. AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 045. PFIZER: SNAPSHOT
TABLE 046. PFIZER: BUSINESS PERFORMANCE
TABLE 047. PFIZER: PRODUCT PORTFOLIO
TABLE 048. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 048. ELI LILLY AND COMPANY: SNAPSHOT
TABLE 049. ELI LILLY AND COMPANY: BUSINESS PERFORMANCE
TABLE 050. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 051. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 051. F. HOFFMANN-LA ROCHE: SNAPSHOT
TABLE 052. F. HOFFMANN-LA ROCHE: BUSINESS PERFORMANCE
TABLE 053. F. HOFFMANN-LA ROCHE: PRODUCT PORTFOLIO
TABLE 054. F. HOFFMANN-LA ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 054. GLAXOSMITHKLINE: SNAPSHOT
TABLE 055. GLAXOSMITHKLINE: BUSINESS PERFORMANCE
TABLE 056. GLAXOSMITHKLINE: PRODUCT PORTFOLIO
TABLE 057. GLAXOSMITHKLINE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 057. SANOFI: SNAPSHOT
TABLE 058. SANOFI: BUSINESS PERFORMANCE
TABLE 059. SANOFI: PRODUCT PORTFOLIO
TABLE 060. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. BIOLOGICS DRUG MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. BIOLOGICS DRUG MARKET OVERVIEW BY TYPE
FIGURE 012. MONOCLONAL ANTIBODIES (MABS) MARKET OVERVIEW (2016-2028)
FIGURE 013. THERAPEUTIC PROTEINS MARKET OVERVIEW (2016-2028)
FIGURE 014. VACCINES MARKET OVERVIEW (2016-2028)
FIGURE 015. BIOLOGICS DRUG MARKET OVERVIEW BY APPLICATION
FIGURE 016. ONLINE SALES MARKET OVERVIEW (2016-2028)
FIGURE 017. PHARMACY MARKET OVERVIEW (2016-2028)
FIGURE 018. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 019. NORTH AMERICA BIOLOGICS DRUG MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 020. EUROPE BIOLOGICS DRUG MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 021. ASIA PACIFIC BIOLOGICS DRUG MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 022. MIDDLE EAST & AFRICA BIOLOGICS DRUG MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 023. SOUTH AMERICA BIOLOGICS DRUG MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. BIOLOGICS DRUG MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. BIOLOGICS DRUG MARKET OVERVIEW BY TYPE
FIGURE 012. MONOCLONAL ANTIBODIES (MABS) MARKET OVERVIEW (2016-2028)
FIGURE 013. THERAPEUTIC PROTEINS MARKET OVERVIEW (2016-2028)
FIGURE 014. VACCINES MARKET OVERVIEW (2016-2028)
FIGURE 015. BIOLOGICS DRUG MARKET OVERVIEW BY APPLICATION
FIGURE 016. ONLINE SALES MARKET OVERVIEW (2016-2028)
FIGURE 017. PHARMACY MARKET OVERVIEW (2016-2028)
FIGURE 018. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 019. NORTH AMERICA BIOLOGICS DRUG MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 020. EUROPE BIOLOGICS DRUG MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 021. ASIA PACIFIC BIOLOGICS DRUG MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 022. MIDDLE EAST & AFRICA BIOLOGICS DRUG MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 023. SOUTH AMERICA BIOLOGICS DRUG MARKET OVERVIEW BY COUNTRY (2016-2028)
